Biogen (BIIB) receives European Commission approval for high dose regimen of Spinraza (Nusinersen) for spinal muscular atrophy

Biogen (BIIB) receives European Commission approval for high dose regimen of Spinraza (Nusinersen) for spinal muscular atrophy.

Biogen's approval of the high dose regimen of Spinraza by the European Commission could signal enhanced treatment options for spinal muscular atrophy, positively impacting the drug's revenue potential. This development might strengthen Biogen's position in the biotechnology sector and could elicit bullish sentiment in both the stock and related biotech equities. Watch for potential peer movement as investors assess the implications for competition in the market.